Top advances of the year: Ovarian cancer
Cancer · 15.03.2024 · 130 (6) · 837-845
DOI: 10.1002/cncr.35135 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 15.12.2023. Verfasst von Melissa A Lumish und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Antineoplastic Agents, Immunoconjugates. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Although cure rates remain low and effective screening strategies are elusive, the recent advances in systemic therapies over the past year highlighted in this review have prolonged survival for women with ovarian cancer. In 2022, the first antibody–drug conjugate for platinum‐resistant ovarian cancer received accelerated US Food and Drug Administration (FDA) approval. Confirmatory studies examining the efficacy of mirvetuximab and other antibody–drug conjugates are underway. In the upfront setting, the first data establishing an overall survival benefit from poly(ADP‐ribose) polymerase inhibitor maintenance was demonstrated after a 7‐year follow‐up period. In contrast, long‐term updates from poly(ADP‐ribose) polymerase inhibitor trials in the noncurative setting reported survival detriments, and the FDA withdrew the respective indications. Several trials attempted to improve upon the standard of care for platinum‐sensitive ovarian carcinoma and those with rare ovarian cancer histologies (carcinosarcoma, clear cell carcinoma) but failed to demonstrate a clinically or statistically meaningful benefit. This leaves the open question of how to further optimize systemic therapy for advanced ovarian carcinoma to improve long‐term survival and cure rates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- National Cancer Institute, Bethesda, Maryland, USA.
ORCID-Profile: William P Tew
Förderung
- NCI NIH HHS
Zitieren
APA
Lumish, M. A., Kohn, E. C., & Tew, W. P. (2024). Top advances of the year: Ovarian cancer. Cancer, 130(6), 837-845. https://doi.org/10.1002/cncr.35135
Vancouver
Lumish MA, Kohn EC, Tew WP. Top advances of the year: Ovarian cancer. Cancer. 2024;130(6):837-845. doi:10.1002/cncr.35135
BibTeX
@article{Lumish2024,
author = {Lumish, Melissa A and Kohn, Elise C and Tew, William P},
title = {Top advances of the year: Ovarian cancer},
journal = {Cancer},
year = {2024},
volume = {130},
number = {6},
pages = {837--845},
doi = {10.1002/cncr.35135}
}
EUVIMED